Ministry of Health and Welfare Approves Clinical Trial Plan for Intravenous Injection of Patients' Own Stem Cells

Going forward, it will be possible to attempt treatments for elderly patients with sarcopenia using their own cells.


'Cell Therapy' to Be Attempted for Elderly Patients with Sarcopenia View original image

On the 27th, the Ministry of Health and Welfare announced that it had held the '4th Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee of 2026' and approved the implementation plan for clinical research on cell therapy for elderly patients with sarcopenia.


The clinical trial approved as appropriate by this committee involves a cell therapy in which a mixture of cells derived from the patient's own fat and bone marrow—specifically, the stromal vascular fraction (SVF) from adipose tissue and bone marrow aspiration concentrate—is collected and administered to elderly patients with sarcopenia. Stromal vascular fraction and bone marrow aspiration concentrate are rich in stem cells and growth factors, and since they are obtained from the patient's own fat and bone marrow, they are classified as low-risk cell therapies with a reduced likelihood of immune rejection.


Sarcopenia in the elderly is a condition characterized by the loss of muscle mass with age. While it was officially recognized as a disease in 2016, there are still no approved treatments. In addition to aging, sarcopenia is caused by multiple factors, including genetics and hormonal changes, highlighting the need for new therapeutic approaches.


In this clinical study, both the stromal vascular fraction and bone marrow aspiration concentrate obtained from the patient will be administered intravenously, allowing a variety of cells and growth factors to act simultaneously. The study aims to verify the safety of the treatment and to determine whether it is effective in actually inhibiting muscle loss.



Meanwhile, six other implementation plans submitted by regenerative medicine institutions were deemed inappropriate and were not approved by the committee on the same day.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing